Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + paclitaxel + tamibarotene
- Development stage
- Discontinued
- Lead developer
- LadRx
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination of three drugs used in oncology. Carboplatin and paclitaxel are well-established chemotherapy agents, often combined as "PC" or "CarboTaxol," and are administered intravenously to treat various cancers by targeting rapidly dividing cells[1][5]. Tamibarotene is a synthetic retinoid, specifically an agonist for retinoic acid receptor alpha/beta, developed to overcome resistance to all-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL)[7][10]. The combination of these three drugs has been investigated in clinical trials for non-small cell lung cancer (NSCLC), but results showed that adding tamibarotene did not improve outcomes compared to carboplatin/paclitaxel alone and was associated with increased toxicity[6].
- Brand names
- paclitaxelTaxolcarboplatinParaplatin
- Other names
- PC plus tamibaroteneCarboTaxol plus tamibarotene
02
Targets
RARA (Retinoic acid receptor alpha)RARB (Retinoic acid receptor beta)DNA
Beyond the preview
Go deeper on carboplatin + paclitaxel + tamibarotene.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + paclitaxel + tamibarotene.